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Abstract
Aim Anastomotic leakage (AL) is one of the most
feared complications after rectal resection. This study
aimed to assess a combination of biomarkers for early
detection of AL after rectal cancer resection.
Method This study was an international multicentre
prospective cohort study. All patients received a pelvic drain
after rectal cancer resection. On the first three postopera-
tive days drain fluid was collected daily and C-reactive pro-
tein (CRP) was measured. Matrix metalloproteinase-2
(MMP2), MMP9, glucose, lactate, interleukin 1-beta
(IL1b), IL6, IL10, tumour necrosis factor alpha (TNFa),
Escherichia coli, Enterococcus faecalis, lipopolysaccharide-
binding protein and amylase were measured in the drain
fluid. Prediction models for AL were built for each postop-
erative day using multivariate penalized logistic regression.
Model performance was estimated by the c-index for dis-
crimination. The model with the best performance was
visualized with a nomogram and calibration was plotted.
Results A total of 292 patients were analysed; 38
(13.0%) patients suffered from AL, with a median inter-
val to diagnosis of 6.0 (interquartile ratio 4.0–14.8)
days. AL occurred less often after partial than after total
mesorectal excision (4.9% vs 15.2%, P = 0.035). Of all
patients with AL, 26 (68.4%) required reoperation. AL
was more often treated by reoperation in patients with-
out a diverting ileostomy (18/20 vs 8/18, P = 0.03).
The prediction model for postoperative day 1 included
MMP9, TNFa, diverting ileostomy and surgical tech-
nique (c-index = 0.71). The prediction model for post-
operative day 2 only included CRP (c-index = 0.69).
The prediction model for postoperative day 3 included
CRP and MMP9 and obtained the best model perfor-
mance (c-index = 0.78).
Conclusion The combination of serum CRP and peri-
toneal MMP9 may be useful for earlier prediction of AL
after rectal cancer resection. In clinical practice, this
combination of biomarkers should be interpreted in the
clinical context as with any other diagnostic tool.
Keywords Anastomotic leakage, rectal resection, early
detection, biomarkers, drain fluid
What does this paper add to the literature?
Anastomotic leakage (AL) is one of the most feared
complications after rectal resection. Early detection is of
paramount importance in order to minimize postopera-
tive morbidity and mortality. This prospective cohort
study showed that a combination of serum CRP and
peritoneal MMP9 may be useful for early prediction of
AL after rectal cancer resection.
Introduction
With the introduction of minimally invasive techniques,
the short-term outcomes of rectal surgery have
improved over the last decades [1,2]. Despite these
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advances, the incidence of anastomotic leakage (AL) has
not been reduced [3]. Moreover, standardized recovery
programmes have shortened hospital stay, with the
downside that AL can become clinically apparent after
discharge resulting in readmission and delayed manage-
ment [4]. Nowadays, 20% of AL is diagnosed after dis-
charge, with a mean time to diagnosis of 6–15 days
[5,6].
The current diagnostic strategy, consisting of on-de-
mand CT scanning, fails to detect AL at an early stage
as half of all leakages require reoperation [7,8]. Delayed
reintervention after false-negative CT scanning is associ-
ated with increased mortality and prolonged hospital
stay [9]. In addition, delay in diagnosis of 2.5 days is
associated with an increase in mortality from 24% to
39% [10]. Hence, early detection is of paramount
importance in order to minimize postoperative morbid-
ity and mortality.
Biomarkers in drain fluid have previously been pro-
posed as an innovative strategy for early detection of
AL. Elevated peritoneal levels of inflammatory cytokines
and lactate as well as decreased pH seemed to be associ-
ated with AL, and measurement of such parameters is
thus of interest for early detection of AL [11]. Further-
more, promising results were shown for lipopolysaccha-
ride-binding protein (LBP) and Enterococcus faecalis in
drain fluid [12,13]. However, implementation in clinical
practice is lagging behind as previous studies were based
on small sample sizes and lacked any estimation of pre-
dictive accuracy.
A systematic review concluded that a combination of
biomarkers yielded improved predictive accuracy com-
pared with separate analysis of biomarkers [14]. There-
fore, we aimed to assess a combination of biomarkers
for prediction of AL after rectal cancer resection and to
determine its predictive accuracy.
Method
Patients
This study was designed as an international multicentre
prospective cohort study. Ten hospitals in the Nether-
lands and Belgium participated in the study. Patients
were included between August 2015 and October
2017. The medical ethics committees of the Erasmus
MC University Medical Centre in the Netherlands and
of the University Hospital Leuven in Belgium approved
this study. Ethical approval was also obtained in the
other participating hospitals. This study was registered
at http://www.isrctn.com/ (study ID 84052649).
Patients aged 18 years and above who underwent
partial mesorectal excision (PME) or total mesorectal
excision (TME) with construction of a colorectal or
coloanal anastomosis were eligible for inclusion. Preg-
nant women and patients who underwent an emergency
procedure were excluded. In addition, patients in whom
no drain fluid was obtained or who underwent surgery
for an indication other than adenocarcinoma were
excluded. All patients gave written informed consent.
The follow-up ended at the first outpatient clinic visit
after hospital discharge.
Collection and storage of drain fluid
All patients received a pelvic drain during surgery. Drain
fluid was collected every morning on the first three
postoperative days. Drain fluid was collected respecting
rules of sterility with a syringe including a needle and
deposited in a 10-ml ethylenediaminetetraacetic acid
(EDTA) tube. The drain fluid reservoir was replaced
after the collection of drain fluid. The EDTA tube was
transported to the laboratory and the drain fluid sam-
ples were centrifuged (at 1955g) for 10 min at 4°C.
Subsequently, the supernatant was removed. Drain fluid
was aliquotted in five cryotubes of 2 ml and stored at
80°C until further analysis. C-reactive protein (CRP)
was measured in peripheral blood samples at the hospi-
tals’ clinical laboratories on the first three postoperative
days.
Drain fluid analysis
Samples were thawed, vortexed and centrifuged for
1 min at 10 000g and 4°C before analysis. All biomark-
ers were measured in duplicate and the means were
taken for further analysis. Matrix metalloproteinases
(MMP2 and MMP9) and cytokines [interleukin 1-beta
(IL1b), IL6, IL10 and tumour necrosis factor alpha
(TNFa)] were measured using ProcartaPlex Multiplex
Immunoassay (Thermo Fisher Scientific, Bleiswijk, The
Netherlands) on a Luminex Magpix machine. High-sen-
sitivity assays were used for cytokine measurement.
Levels of a-amylase, glucose and lactate were measured
using Roche/Hitachi cobas c systems from Roche Diag-
nostics (Indianapolis, Indiana, USA). LBP was mea-
sured with enzyme linked immunosorbent assay
(ELISA; R&D Systems, Minneapolis, Minnesota, USA)
according to the manufacturer’s instruction. Escherichia
coli and E. faecalis were measured using a semi-quanti-
tative real-time PCR strategy. Prior to DNA isolation,
500 ll of drain fluid was spiked with 5 ll of Phocine
Herpes Virus (PhHV) as an internal control from the
European Virus Archive (EVAg). Samples were spun for
5 min at 8000g and the pellets resuspended in 180 ll
buffer (20 mM Tris, 2 mM EDTA, 1% Tween 80 and
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50 mg/ml lysozyme). The samples were incubated at
37°C with shaking at 600 rpm for 30 min after which
25 ll of proteinase K was added followed by a 2-h
incubation at 56°C at 700 rpm. DNA extraction was
performed using a Macherey-Nagel NucleoSpin Tissue
kit (Bioke, Leiden, the Netherlands). Template DNA
was eluted in elution buffer in a total volume of 100 ll.
Subsequently, primers for E. coli and E. faecalis were
added in accordance with the previously published pro-
tocol [15]. The StepOnePlus Real-Time PCR System
(Applied Biosystems, Bleiswijk, the Netherlands) was
used for RT-PCR. Threshold cycles (Ct) were corrected
for differences in extraction efficiency using the thresh-
old cycle of the internal control PhHV.
Clinical data assessment
Patient characteristics (age, gender, body mass index,
medication use, bowel preparation, smoking, alcohol
abuse, American Society of Anesthesiologists score, previ-
ous abdominal surgery, indication for surgery, preopera-
tive radiotherapy, preoperative chemotherapy, location of
lesion) and surgical characteristics (surgical procedure, sur-
gical technique, conversion, construction of anastomosis,
configuration of anastomosis, diverting ileostomy) were
prospectively registered. Creation of the anastomosis was
registered as ‘stapler’ or ‘manual’. Manual anastomosis
was performed using interrupted coloanal sutures with a
hand-sewn technique. If the anastomosis was constructed
with a stapler and additional manual sutures were added
this was registered as stapled. Transanal TME was defined
as follows: part of a TME being performed with transanal
assistance. This includes a semi-rigid platform with rigid
instruments to perform a down-to-up TME.
AL was the primary outcome of interest, being
defined as a clinically manifest insufficiency of the anas-
tomosis leading to a clinical state requiring treatment
(i.e. grade B/C) [7]. AL was confirmed by either endo-
scopy, CT scan and/or contrast enema or reoperation.
Fistulas communicating with the anastomosis on CT
scan were classified as AL together with presacral
abscesses if extravasation of the colonic contrast was vis-
ible on radiological imaging. In addition, postoperative
indicators (time to discharge, postoperative complica-
tions with their respective treatment strategies, readmis-
sion, reoperation and mortality) were prospectively
registered. Elective stoma reversals were not registered
as reoperation.
Statistical analysis
Continuous variables were described as median  in-
terquartile range (IQR) and compared with the Mann–
Whitney U-test. Categorical variables were described as
percentages and compared with the chi-square test or
Fisher’s exact test when needed. Comparisons of
biomarkers were corrected for multiple testing using
Holm’s method per postoperative day [16]. A multiple
imputation procedure was performed to impute missing
data based on 10 completed datasets. For each postop-
erative day, multivariate penalized logistic regression
models were constructed including clinically relevant
baseline characteristics (age, gender, nonsteroidal anti-
inflammatory drugs, corticosteroids, diverting Ileost-
omy, surgical procedure, approach) and all biomarkers.
Prediction models for each postoperative day were built
including covariates with a P-value < 0.1. Internal vali-
dation using the bootstrap method was done to obtain
corrected estimates of model performance to avoid
overfitting. Model performance was estimated by Har-
rell’s concordance index (the c-index). The c-index mea-
sures how adequate the model is at discriminating
between the outcome of interest, and represents the
probability that, in a randomly selected pair of patients,
the model assigns a higher risk to the patient who is
truly high risk compared with the patient who is truly
low risk. A c-index of 0.5 indicates no association
between prediction and true outcome and a value of
1.0 indicates perfect association. A c-index of more than
0.75 is considered clinically useful [17]. A calibration
plot of the model with the best c-index was built show-
ing the relationship between the observed and predicted
probability of the outcome. The observed and expected
rates are similar in a well-calibrated model. The final
model was visualized using a nomogram and captured
in an online calculator (https://www.evidencio.c
om/models/show/1537). Two-sided P-values < 0.05
were considered statistically significant. Analyses were
performed using SPSS v.22 (IBM Corp., Armonk, New
York, USA) and the NLME, LATTICE, ARM, AOD
and RMS packages in R v.3.3.3 (http://www.r-project.
org).
Results
Study population
A total of 310 patients were included. Nine patients
were excluded because no drain fluid was obtained, and
nine were excluded due to another surgical indication
than rectal adenocarcinoma. In the end, 292 patients
were eligible for analysis.
Table 1 represents baseline characteristics of the
study population. The median time of follow-up was
28.0 days (IQR 17.0–35.0). The median time to dis-
charge was 7.0 days (IQR 5.0–11.0). In total, 42
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(14.4%) patients were readmitted to the hospital and 38
(13.0%) underwent reoperation. Infection at the drain
insertion site was reported in three (1.0%) patients. No
other complications of the pelvic drain were reported.
Two (0.7%) patients died. One patient died of AL and
the other patient died 2 days after hospital discharge of
an unknown reason as no autopsy was performed.
Anastomotic leakage
A total of 38 (13.0%) patients suffered from AL. No
differences in patient characteristics were observed for
patients with and without AL. The incidence of AL was
no different for patients with and without diverting
ileostomy (11.4% vs 14.9%, P = 0.371). AL occurred
less often after PME than after TME (4.9% vs 15.2%,
P = 0.035) (Table 1).
AL was clinically manifest as a presacral abscess in
five patients. The median time to diagnosis was 6.0 days
(IQR 6.0–14.8). Patients with AL had a significantly
longer hospital stay (16.0 days vs 6.0 days, P ≤ 0.001).
Production of drain fluid was no different for patients
with and without AL (day 1, 155 ml vs 180.0 ml,
P = 0.664; day 2, 97.5 ml vs 100.0 ml, P = 0.435; day
3, 60.0 ml vs 90.0 ml, P = 0.141).
In 30 (78.9%) patients AL was confirmed by a CT
scan, in 5 (13.2%) by proctoscopy and in 1 (2.6%)
patient by reoperation. Of all patients with AL, 26
(68.4%) required reoperation whereas 12 (31.6%) were
treated more conservatively (antibiotics, drainage or
Endo-sponge). AL was more often treated by reopera-
tion in patients without a diverting ileostomy (18/20 vs
8/18, P = 0.03).
Biomarkers
Table 2 compares the levels of biomarkers for patients
with and without AL per postoperative day. Table 3
represents outcomes of multivariate penalized logistic
regression analyses per postoperative day. Prediction
models for each postoperative day were built including
covariates with a P-value < 0.1 in the multivariate analy-
sis. The prediction model for postoperative day 1
included MMP9, TNFa, diverting ileostomy and surgi-
cal technique. The prediction model for postoperative
day 2 only included CRP. The prediction model for
postoperative day 3 included both CRP and MMP9.
The prediction model of postoperative day 1 had a c-
index of 0.71 whereas the prediction model of postop-
erative day 2 had a c-index of 0.69. These prediction
models were thus lacking discrimination and therefore
were not considered to be clinically useful. On the con-
trary, the prediction model of postoperative day 3,
including CRP and MMP9, had a c-index of 0.78. This
c-index indicated that for 78% of the time the model
assigned a higher probability to a patient with AL than
a patient without AL. For the prediction model of post-
operative day 3, a nomogram was constructed facilitat-
ing the calculation of the individual risk of AL after
rectal cancer resection based on CRP and MMP9 on
postoperative day 3 (Fig. 1). An online calculator was
built for this nomogram at https://www.evidencio.
com/models/show/1537.
Calibration was determined to estimate model per-
formance with a calibration plot. In a calibration plot
the predicted probability is plotted against the corre-
sponding observed probability in the dataset. Ideally,
this depicts a diagonal line and calibration is quantified
by the mean absolute error. Figure 2 shows the calibra-
tion plot of the prediction model of postoperative day 3
(mean absolute error = 0.025).
Discussion and conclusions
This international multicentre prospective cohort study
showed that a combination of serum CRP and peri-
toneal MMP9 may be useful for early prediction of AL
after rectal cancer resection. The combination of these
biomarkers can estimate the individual risk of AL after
rectal cancer resection on the third postoperative day,
which was 3 days earlier than the median time to diag-
nosis (6 days).
As with any other biomarker in clinical practice, this
tool only assesses the risk of AL; it requires confirma-
tion through additional imaging. However, this tool
might enable timely intervention and subsequently min-
imize morbidity and mortality. For example, if this tool
shows that a patient has high risk of AL on the third
postoperative day and AL is subsequently confirmed by
additional imaging even before the leak becomes clini-
cally apparent, early reintervention could minimize the
consequences of AL. So, this tool facilitates decision-
making for surgeons even before clinical symptoms
occur [18].
Serum CRP is already a useful negative predictor for
AL after anterior resection [19,20]. Nevertheless, serum
CRP monitoring lacks specificity and positive predictive
value (PPV) for AL, because the CRP level also rises
due to other inflammatory complications [21]. Previous
research on biomarkers for AL showed that local
biomarkers from peritoneal fluid were more specific
than systemic biomarkers [22]. The present study
showed that peritoneal MMP9 was predictive for AL,
and therefore this biomarker has additional value in pre-
diction of AL over serum CRP alone. Furthermore, the
c-index of 0.78 of this combination showed adequate
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Table 1 Patient and surgical characteristics of patients with and without anastomotic leakage (AL).
Total no. of
patients (n = 292)
No AL
(n = 254, 87.0%)
AL
(n = 38, 13.0%) Missing P-value
Patient characteristics
Age (years), median  IQR 63.0 (57.0–71.0) 63.5 (57.5–71.0) 60.5 (53.8–68.5) 0 (0.0%) 0.135
Gender
Male 193 (66.1%) 167 (65.7%) 26 (68.4%) 0 (0.0%) 0.745
Female 99 (34.0%) 87 (34.4%) 12 (31.6%)
BMI (kg/m2), median  IQR 25.8 (23.5–28.7) 25.8 (23.3–28.7) 25.9 (24.2–29.2) 1 (0.3%) 0.546
Corticosteroids 17 (5.8%) 14 (5.5%) 3 (7.9%) 2 (0.7%) 0.475*
NSAIDs 8 (2.7%) 7 (2.8%) 1 (2.6%) 2 (0.7%) 1.000*
Bowel preparation 244 (83.6%) 209 (82.3%) 35 (92.1%) 25 (8.6%) 1.000*
Smoking 38 (13.0%) 31 (12.2%) 7 (18.4%) 10 (3.4%) 0.304*
Alcohol abuse 39 (13.4%) 32 (12.6%) 7 (18.4%) 10 (3.4%) 0.378
ASA score
I 45 (15.4%) 37 (14.6%) 8 (21.1%) 2 (0.7%) 0.468*
II 181 (62.0%) 156 (61.4%) 25 (65.8%)
III 62 (21.2%) 57 (22.4%) 5 (13.2%)
IV 2 (0.7%) 2 (0.8%) 0 (0.0%)
Previous abdominal surgery 100 (34.2%) 90 (35.4%) 10 (26.3%) 1 (0.3%) 0.263
Clinical tumour stage
T1 14 (4.8%) 13 (5.1%) 1 (2.6%) 44 (15.1%) 0.871*
T2 72 (24.7%) 62 (24.4%) 10 (26.3%)
T3 144 (49.3%) 123 (48.4%) 21 (55.3%)
T4 18 (6.2%) 16 (6.3%) 2 (5.3%)
Clinical nodal stage
N0 101 (34.6%) 86 (33.9%) 15 (39.5%) 0.600
N ≥ 1 139 (47.6%) 119 (46.9%) 17 (44.7%)
Preoperative radiotherapy 155 (53.1%) 135 (53.1%) 20 (52.6%) 1 (0.3%) 0.933
Short course 58 (37.4%) 52 (38.5%) 6 (30.0%)
Long course 89 (57.4%) 77 (57.0%) 12 (60.0%)
Preoperative chemotherapy 102 (34.9%) 87 (34.3%) 15 (39.5%) 1 (0.3%) 0.540
Location of lesion from anal
verge (cm), median  IQR
10.0 (6.0–13.0) 10.0 (6.0–14.0) 9.0 (5.0–12.0) 16 (5.5%) 0.169
Surgical characteristics
Procedure
PME 61 (20.9%) 58 (22.8%) 3 (7.9%) 0 (0.0%) 0.035
TME 231 (79.1%) 196 (77.2%) 35 (92.1%)
Surgical technique
Open 11 (3.8%) 10 (3.9%) 1 (2.6%) 0 (0.0%) 0.736*
Laparoscopic 161 (55.1%) 142 (55.9%) 19 (50.0%)
Transanal 120 (41.1%) 102 (40.2%) 18 (47.4%)
Conversion 8 (2.7%) 8 (3.1%) 0 (0.0%) 0 (0.0%) 0.598*
Construction of anastomosis
Manual 43 (14.7%) 39 (15.4%) 4 (10.5%) 2 (0.7%) 0.423
Stapler 247 (84.6%) 213 (83.9%) 34 (89.5%)
Configuration of anastomosis
Side-to-side 4 (1.4%) 4 (1.6%) 0 (0.0%) 31 (10.6%) 0.861*
Side-to-end 173 (59.2%) 147 (57.9%) 26 (68.4%)
End-to-end 79 (27.1%) 70 (27.6%) 9 (23.7%)
End-to-side 5 (1.7%) 5 (2.0%) 0 (0.0%)
Diverting ileostomy 158 (54.1%) 140 (55.1%) 18 (47.4%) 0 (0.0%) 0.371
Bold values indicate significance.
ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range.
*Fisher’s exact test.
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discrimination, which is important in a diagnostic set-
ting where the classification of patients into different
groups is of major interest.
MMP9 is a matrix metalloproteinase which plays a
role in the degradation of extracellular matrix proteins,
especially collagen, and is actively involved in the
inflammation reaction and wound healing process
[23,24]. Previously, experimental studies have investi-
gated the association between MMPs and colorectal
AL. MMPs negatively affect anastomotic healing
[25,26] whereas MMP inhibitors provided enhanced
breaking strength of colonic anastomoses [27]. The
most pronounced collagen loss provoked by MMP9 was
seen in the suture-holding zone of colonic anastomoses
[28]. In addition, in an experimental model of bacterial
peritonitis anastomotic MMP9 activity was increased
3 days after operation [29]. Translation to clinical
research obtained similar results. Patients with elevated
levels of MMP1, MMP2 and MMP9 in perioperative
biopsies from the colon more often had AL [30]. Actu-
ally, peritoneal MMP9 had already been evaluated as
biomarker for AL. Contradictory literature exists for
colorectal resection [31,32], but for rectal resection a
pilot study showed that peritoneal MMP9 levels
measured 4 h after surgery were increased in patients
who developed AL [33]. However, it remains unknown
whether this association represents a causal relationship
or is a consequential effect of AL.
In rectal cancer surgery, diversion is commonly
applied to protect the anastomosis from leakage [34].
However, the incidence of AL was no different for
patients with and without a diverting ileostomy (11.4%
vs 14.9%). Nevertheless, in patients without a diverting
ileostomy, AL was more often treated by reoperation
than in patients with a diverting ileostomy (18/20 vs
8/18, P = 0.03). These results suggest that a diverting
ileostomy allows less invasive treatment strategies.
Accordingly, it was previously shown from population-
based data of the Dutch ColoRectal Audit (DCRA) that
a high tendency towards stoma construction in rectal
cancer surgery did not reduce the incidence of AL [35].
The reported incidence of AL of 13.0% is high com-
pared with several previous studies (3.0–11.1%)
[36,37]. We hypothesize that the prospective design
and inclusion of only rectal resections contributed to
this relatively high incidence of AL. Another explana-
tion is that the definition of AL varies and that some
atypical presentations of leakages such as presacral
Table 2 Comparison of biomarker levels for patients with and without anastomotic leakage (AL).
AL
Postoperative day 1 Postoperative day 2 Postoperative day 3
n Median Q1 Q3 P-value n Median Q1 Q3 P-value n Median Q1 Q3 P-value
MMP2 9 105
(pg/ml)
Y 37 0.7 0.5 1.2 1.000 31 1.0 0.6 1.4 1.000 31 1.1 0.7 2.1 1.000
N 248 0.7 0.4 1.1 236 1.0 0.6 1.4 230 1.2 0.7 1.7
MMP9 9 105
(pg/ml)
Y 37 3.2 0.9 10.8 0.450 31 1.7 0.4 7.0 1.000 32 2.0 0.5 5.0 0.011
N 247 2.0 0.9 4.1 235 1.0 0.5 2.0 231 0.6 0.3 1.5
Glucose (mM) Y 37 2.0 0.4 3.8 0.252 38 0.2 0.1 2.4 < 0.001 35 0.3 0.1 3.1 0.011
N 247 3.4 1.5 4.6 241 2.4 0.1 4.7 238 2.9 0.1 5.0
Lactate (mM) Y 37 10.5 6.9 14.5 1.000 38 12.5 9.1 19.7 1.000 37 11.3 8.1 19.2 0.444
N 248 9.1 6.2 13.2 242 11.1 6.4 17.3 243 9.2 5.2 14.9
CRP (mg/ml) Y 36 69.5 35.0 105.8 0.459 36 152.5 83.5 215.5 < 0.001 37 170.0 113.8 290.5 < 0.001
N 241 50.0 30.9 80.0 213 86.0 47.1 135.9 215 78.0 41.0 125.0
IL1b (pg/ml) Y 37 61.1 31.7 263.5 0.341 32 138.1 46.7 536.8 0.011 31 190.0 28.6 3271.1 < 0.001
N 247 47.1 19.6 132.3 236 39.8 13.4 151.5 232 30.3 9.3 142.9
IL6 (pg/ml) Y 36 69717.7 19267.2 76184.2 1.000 32 73454.5 23889.4 76334.1 1.000 31 46178.8 17483.5 76070.8 0.301
N 246 51635.3 23484.4 76070.8 236 41860.7 17483.5 75786.4 232 24738.2 11239.9 68858.8
IL10 (pg/ml) Y 37 249.7 141.3 594.6 0.584 32 176.3 84.4 630.8 0.080 31 128.3 38.6 554.2 0.072
N 247 204.8 109.7 405.5 236 99.1 51.8 220.8 232 62.4 30.0 136.4
TNFa (pg/ml) Y 37 37.3 23.6 128.8 0.156 32 23.1 12.9 67.2 1.000 31 45.2 14.2 79.7 0.036
N 246 30.1 16.4 59.1 237 21.5 12.0 39.8 231 17.7 9.9 34.0
Escherichia
coli (Ct)
Y 37 34.2 32.4 35.8 1.000 33 34.8 31.4 37.5 1.000 30 34.3 26.7 36.4 1.000
N 247 34.6 32.4 37.0 231 34.6 32.4 36.7 227 34.7 32.9 36.6
Enterococcus
faecalis (Ct)
Y 38 26.3 25.2 26.9 1.000 33 26.5 25.4 27.5 1.000 32 26.2 25.1 27.4 1.000
N 248 26.2 25.1 27.1 234 26.0 25.0 27.0 228 25.9 25.1 27.0
LBP (lg/ml) Y 38 3.6 1.9 5.0 1.000 34 5.5 3.5 6.6 1.000 31 6.2 4.6 7.0 1.000
N 248 3.2 2.2 4.4 237 5.1 4.0 6.1 231 5.6 4.5 6.7
Amylase (U/l) Y 36 36.0 14.3 84.8 0.584 38 30.5 13.5 47.0 1.000 37 24.0 17.5 45.0 1.000
N 243 24.0 13.0 41.0 243 28.0 18.0 45.0 244 25.0 15.0 37.0
Bold values indicate significance.
CRP, C-reactive protein; IL, interleukin; LBP, lipopolysaccharide-binding protein; MMP, matrix metalloproteinase; n, number of
patients; Q1, first quartile; Q3, third quartile; TNFa, tumour necrosis factor alpha.
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abscesses or rectovaginal fistulas are not always
included. In addition, the Dutch Snapshot study
reported a comparable incidence of 13.4% within
30 days postoperation [4].
Over the last decade, our research group has been
involved in the search for a reliable biomarker for AL
after colorectal resection. In a clinical trial (the APPEAL
study), we demonstrated that PCR in drain fluid for
E. faecalis could be predictive for AL after colorectal
resection [13]. However, the relatively low PPV of
30.2% on the third postoperative day indicated a sub-
stantial number of false positives. Therefore, the present
study was conducted with the aim of obtaining a com-
bination of biomarkers with increased predictive accu-
racy. In addition, the previous study showed that an
increase of one standard deviation in the average level
of LBP on postoperative day 1 is associated with an
increased risk of leakage of 1.6 [12]. LBP is an acute
phase protein that binds to lipopolysaccharide (LPS) to
elicit an immune response to Gram-negative bacteria
[38]. However, the present study did not confirm these
results, possibly due to different drain locations as the
previous study obtained drain fluid from intra-abdomi-
nal drains whereas the present study used pelvic drains
which were positioned extraperitoneally. Furthermore,
the different microbiome of patients with colon and
rectal cancer may be another explanation because the
previous study also included colonic resections [39,40].
This previous study showed promising results for drain
fluid analysis on the first three postoperative days.
Therefore, we decided to limit drain fluid collection to
this interval.
The GRECCAR 5 trial has shown that pelvic drai-
nage after rectal excision for rectal cancer does not
reduce AL [41]. On the other hand, pelvic drainage
was not found to be detrimental [42]. In this study,
only three (1.0%) patients suffered from infection at the
drain insertion site, which could be managed without
invasive treatment strategies. So the opportunity for
early detection of AL after rectal resection with innova-
tive drain fluid analysis might justify pelvic drainage
after rectal resection.
Table 3 Outcomes of multivariate penalized logistic regression for anastomotic leakage (AL) per postoperative day.
Postoperative day 1 Postoperative day 2 Postoperative day 3
OR
95% CI
(lower)
95% CI
(upper) P-value OR
95% CI
(lower)
95% CI
(upper) P-value OR
95% CI
(lower)
95% CI
(upper) P-value
MMP2 (pg/ml) 1.011 0.962 1.063 0.661 1.020 0.955 1.090 0.556 1.025 0.986 1.066 0.216
MMP9 (pg/ml) 1.106 0.995 1.229 0.063* 1.094 0.952 1.257 0.203 1.130 0.982 1.301 0.088‡
Glucose (mM) 0.939 0.751 1.176 0.585 0.916 0.728 1.152 0.453 0.920 0.734 1.152 0.466
Lactate (mM) 0.990 0.890 1.101 0.854 0.993 0.912 1.081 0.869 0.987 0.917 1.063 0.737
CRP (mg/ml) 1.068 0.981 1.162 0.128 1.057 1.005 1.111 0.030† 1.064 1.013 1.118 0.013‡
IL1b (pg/ml) 1.002 0.992 1.012 0.702 0.999 0.992 1.006 0.787 1.001 0.999 1.003 0.522
IL6 (pg/ml) 0.980 0.847 1.135 0.787 1.052 0.899 1.230 0.529 0.939 0.788 1.119 0.481
IL10 (pg/ml) 0.999 0.980 1.019 0.954 1.044 0.940 1.159 0.424 1.110 0.959 1.284 0.161
TNFa (pg/ml) 1.037 0.998 1.077 0.062* 0.991 0.969 1.014 0.453 1.011 0.996 1.026 0.136
Escherichia coli (Ct) 0.975 0.852 1.115 0.707 0.947 0.830 1.081 0.422 1.029 0.905 1.169 0.664
Enterococcus
faecalis (Ct)
1.072 0.756 1.520 0.697 1.179 0.820 1.695 0.373 1.009 0.703 1.448 0.960
LBP (lg/ml) 0.913 0.704 1.184 0.492 0.910 0.708 1.170 0.462 0.888 0.686 1.149 0.365
Amylase (U/l) 1.000 0.998 1.003 0.827 1.001 0.998 1.003 0.648 1.000 0.999 1.001 0.547
Age 0.978 0.944 1.013 0.222 0.973 0.936 1.010 0.154 0.986 0.948 1.027 0.503
Gender 0.931 0.415 2.088 0.862 0.866 0.367 2.044 0.743 0.698 0.275 1.772 0.449
NSAIDs 0.719 0.131 3.953 0.704 0.454 0.051 4.042 0.479 1.018 0.172 6.028 0.985
Corticosteroids 1.066 0.263 4.315 0.928 1.132 0.252 5.093 0.871 1.087 0.267 4.430 0.908
Diverting ileostomy 0.478 0.205 1.116 0.088* 0.485 0.195 1.208 0.120 0.575 0.219 1.511 0.261
Procedure 2.829 0.888 9.014 0.079* 2.540 0.787 8.193 0.119 2.229 0.603 8.239 0.229
Surgical technique 0.756 0.151 3.787 0.733 0.804 0.152 4.252 0.797 1.047 0.197 5.557 0.957
CI, confidence interval; CRP, C-reactive protein; IL, interleukin; LBP, lipopolysaccharide-binding protein; MMP, matrix metallo-
proteinase; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.
*These variables were added to the prediction model of postoperative day 1.
†These variables were added to the prediction model of postoperative day 2.
‡These variables were added to the prediction model of postoperative day 3.
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Measurements of MMP9 can easily be implemented
as Luminex is a commonly used method in clinical labo-
ratories. It is a fast method and relatively cheap. How-
ever, there were some limitations. First of all,
dislocation of the drain may have influenced drain fluid
composition [43]. Secondly, intra-operative spillage
could have affected drain fluid composition by eliciting
an inflammatory response. In addition, the emerging
transanal technique may have an effect on pelvic con-
tamination, although no evidence for this exists.
Since prediction models tend to perform better on
data on which the model was constructed, external vali-
dation is essential before implementing prediction mod-
els in clinical practice [44]. Furthermore, a phase II
diagnostic study is required to confirm that this tool
truly predicts AL in a time-changing direction which
runs from the diagnostic test forward to diagnosis [45].
In this manner, the effect on time to diagnosis can be
assessed prospectively. In the end, the effect of early
detection on morbidity and mortality requires phase III
diagnostic research.
This international multicentre prospective cohort
study showed that a combination of serum CRP and
peritoneal MMP9 may be useful for earlier prediction of
AL after rectal cancer resection. Nevertheless, it is
important to mention that this tool should never
replace clinical observations, implying that the outcomes
of this tool should be interpreted in the clinical context
as with any other diagnostic tool.
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